RARE

Ultragenyx Pharmaceutical Inc. (RARE) | Rumor.io

Ultragenyx Pharmaceutical

RARE

Attention (50-day avg)0.01%

Attention rank (50-day avg)#395

Bullish sentiment (50-day avg)72%

Price to earnings ratio-2.47

Market capitalization1.4B

Earnings per share-5.83

Dividend yield (TTM)—

Revenue (annual)673M

Net income (annual)-575M

Social

What share of all stock conversation is about RARE?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0.01% +0.01	0% -0.05	0.02% +0.02	0% 0

Sep 29

$RARE has been identified as an undervalued biotech stock with a strong pipeline and commercial suite, including recent FDA approval for pediatric Sanfilippo syndrome and two potential PRVs for non-dilutive cash.
Analysts have set an average 12-month price target of 27.47 on RARE, with some targeting as high as $68.00, and the stock is poised for a massive valuation reset with two gene therapy launches ramping up.
$RARE's valuation is significantly compressed compared to established rare-disease companies, with a market cap of around $1.4B despite generating over $700M in trailing revenue and having six FDA-approved therapies.

Generated by AI

Sentiment

Of the messages about RARE that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	97.5% +28.27	82.05% -4.07	71.84% -13.43	62.23% -18.14
Bearish	2.5% -28.27	17.95% +4.07	28.16% +13.43	37.77% +18.14

Bullish· Sep 22

The stock price is expected to reach $20 and potentially $30, driven by takeover speculation and the company's growing revenue and pipeline.
The company's recent approvals and strong financials, including $436M in cash and two potential PRVs worth $360-410M, are attracting attention and could lead to a takeover.
The stock has broken out and is expected to continue upward, with a target of $17-$18 and potential for Big Pharma to acquire the company, leading to a significant increase in value.

Bearish· Sep 18

The company's management has been accused of weak leadership, with one analyst describing the company's focus as solely on cost-cutting and revenue vs. expenses, rather than innovative pipeline development.
The stock's price has been suppressed by a combination of shorts, puts, and selling option contracts, with many analysts predicting a further decline in the stock's value.
The company's recent performance has been compared to a "pure Revenue vs expenses play", with some analysts suggesting that the stock's valuation has been significantly impacted, making it an attractive target for a potential takeover.

Generated by AI

Topics

Of the messages about RARE that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Technical Analysis	100%	16.67%	25.33%	8.58%
Announcements	0%	83.33%	50.91%	61.58%
Analysts	0%	0%	22.98%	18.73%
Earnings	0%	0%	0.78%	0.54%
Controversies	0%	0%	0%	0.58%
Macro	0%	0%	0%	9.98%

Analysts· Sep 3

Analysts at JPMorgan, Cantor Fitzgerald, and Wedbush have lowered their price targets on Ultragenyx Pharmaceutical Inc. (RARE) following the failure of its Phase 3 Aspire study of GTX-102 in Angelman syndrome.
The accelerated approval for Ultragenyx's one-time gene therapy, Genglycos, in August signals potential success for UX111 later this month, which targets Sanfilippo syndrome type A.
Analysts at Jefferies, Baird, and William Blair have downgraded Ultragenyx to Neutral or In Line ratings, citing the setback in the Phase 3 ASPIRE trial and the company's heavy expense burden.

Announcements· Dec 30

Ultragenyx Pharmaceutical Inc. completed the rolling submission of its Biologics License Application (BLA) to the U.S. FDA for DTX401, an AAV gene therapy candidate for Glycogen Storage Disease Type Ia.
If approved, DTX401 will be the first therapy approved to treat the underlying cause of GSDIa, a rare genetic disorder.
Ultragenyx's BLA submission for DTX401 is supported by data from a study, and the company is awaiting FDA approval.

Technical Analysis· Apr 19

Technical alerts for $RARE include a Shooting Star Candlestick and 5 more alerts, but none are specified.
The stock is expected to pull back to $62.50 and potentially bounce back to $66+.
A top reversal is predicted for $RARE, but the timeframe for this event is uncertain.

Generated by AI

Community

Of the messages about RARE, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	19.23%	13.54%	11.17%	34.48%
Newcomers	80.77%	86.46%	88.83%	65.52%

Regulars· Sep 18

Cantor Fitzgerald raised the price target on $RARE to $39 from $33, citing the approval of FAYUVI as a "much-needed win" for Ultragenyx.
Institutional investors are likely to be bought out by a biopharmaceutical company, potentially at a price of 6X or 7X annual forecasted future sales.
The market is undervaluing Ultragenyx, with a current price that is disconnected from the company's business, and a valuation of around $24 per share is suggested.

Newcomers· Sep 29

The newcomer is setting a price target of $20 for RARE, expecting a surge after a potential PRV sale news.
RARE is undervalued, with a market cap of $1.4B despite generating $700M in trailing revenue, and is expected to have a valuation reset due to its pipeline and existing commercial suite.
The newcomer is hopeful that RARE can hold its price, and believes that the company's future looks brighter than its current share price suggests, with a potential price target of $45.

Generated by AI

News

H.C. Wainwright reiterates Ultragenyx stock rating on FDA approval

4d agoInvesting.com

RARE Stock Climbs This Week As Investors Look Past Trial Failure To Gene Therapy Launches, Trial Results

Ultragenyx shares are trading around $16 after gaining about 9% this week, rebounding from the $12.73 low hit earlier this month.

7d agoYahoo Finance

FDA Approves Fayuvi. What Does It Mean for Ultragenyx (RARE)’s 2027 Profitability Target?

8d agoYahoo Finance

Analysts Offer Insights on Healthcare Companies: Helus Pharma (HELP), Ultragenyx Pharmaceutical (RARE) and Novavax (NVAX)

Tipranks Press Release.

8d agoThe Globe and Mail

Analysts Offer Insights on Healthcare Companies: Merck & Company (MRK), Envista Holdings (NVST) and Ultragenyx Pharmaceutical (RARE)

Detailed price information for Merck & Company (MRK-N) from The Globe and Mail including charting and trades.

8d agoThe Globe and Mail

Weekly Note: Ultragenyx (RARE): FAYUVI Full Approval Clears The Binary: Upgrade To Buy, Execute Stage Two

9d agoSeeking Alpha

Also Discussed

Investors talking about RARE also mention

#	Name	Attention
1	Mereo BioPharma Group plc ADRMREO	0.01%-0.01
2	Regenxbio Inc.RGNX	0%+0
3	Denali Therapeutics Inc.DNLI	0%new
4	BioMarin Pharmaceutical IncBMRN	0%+0
5	SWTX - SpringWorks Therapeutics, Inc.	——
6	Neurocrine Biosciences, Inc.NBIX	0%new
7	uniQure N.V.QURE	0.02%+0.01
8	Ionis Pharmaceuticals, Inc.IONS	0%new
9	BPMC - Blueprint Medicines Corporation	——
10	Agios Pharmaceuticals, Inc.AGIO	0%0

Ultragenyx Pharmaceutical Inc.

Healthcare
Biotechnology

Ultragenyx Pharmaceutical Inc. is a biopharmaceutical company focused on developing and commercializing treatments for rare and ultra-rare genetic diseases. Its current portfolio includes approved medicines and other therapies designed to address serious conditions with limited treatment options, spanning metabolic, skeletal, and other inherited disorders. The company works across multiple modalities, including biologics, small molecules, gene therapy, and nucleic acid-based approaches, to target diseases where the underlying biology is well understood and patient need is high. Ultragenyx serves patients through marketed products such as therapies for X-linked hypophosphatemia, long-chain fatty acid oxidation disorders, mucopolysaccharidosis, and homozygous familial hypercholesterolemia. Headquartered in Novato, California, Ultragenyx plays a specialized role in the rare-disease market by combining commercialization capabilities with ongoing research and development in genetic medicine.

Website

Location

60 Leveroni Court

Novato, CA, 94949

United States

Social

What share of all stock conversation is about RARE?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0.01% +0.01	0% -0.05	0.02% +0.02	0% 0

Sep 29

$RARE has been identified as an undervalued biotech stock with a strong pipeline and commercial suite, including recent FDA approval for pediatric Sanfilippo syndrome and two potential PRVs for non-dilutive cash.
Analysts have set an average 12-month price target of 27.47 on RARE, with some targeting as high as $68.00, and the stock is poised for a massive valuation reset with two gene therapy launches ramping up.
$RARE's valuation is significantly compressed compared to established rare-disease companies, with a market cap of around $1.4B despite generating over $700M in trailing revenue and having six FDA-approved therapies.

Generated by AI

Sentiment

Of the messages about RARE that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	97.5% +28.27	82.05% -4.07	71.84% -13.43	62.23% -18.14
Bearish	2.5% -28.27	17.95% +4.07	28.16% +13.43	37.77% +18.14

Bullish· Sep 22

The stock price is expected to reach $20 and potentially $30, driven by takeover speculation and the company's growing revenue and pipeline.
The company's recent approvals and strong financials, including $436M in cash and two potential PRVs worth $360-410M, are attracting attention and could lead to a takeover.
The stock has broken out and is expected to continue upward, with a target of $17-$18 and potential for Big Pharma to acquire the company, leading to a significant increase in value.

Bearish· Sep 18

The company's management has been accused of weak leadership, with one analyst describing the company's focus as solely on cost-cutting and revenue vs. expenses, rather than innovative pipeline development.
The stock's price has been suppressed by a combination of shorts, puts, and selling option contracts, with many analysts predicting a further decline in the stock's value.
The company's recent performance has been compared to a "pure Revenue vs expenses play", with some analysts suggesting that the stock's valuation has been significantly impacted, making it an attractive target for a potential takeover.

Generated by AI

Topics

Of the messages about RARE that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Technical Analysis	100%	16.67%	25.33%	8.58%
Announcements	0%	83.33%	50.91%	61.58%
Analysts	0%	0%	22.98%	18.73%
Earnings	0%	0%	0.78%	0.54%
Controversies	0%	0%	0%	0.58%
Macro	0%	0%	0%	9.98%

Analysts· Sep 3

Analysts at JPMorgan, Cantor Fitzgerald, and Wedbush have lowered their price targets on Ultragenyx Pharmaceutical Inc. (RARE) following the failure of its Phase 3 Aspire study of GTX-102 in Angelman syndrome.
The accelerated approval for Ultragenyx's one-time gene therapy, Genglycos, in August signals potential success for UX111 later this month, which targets Sanfilippo syndrome type A.
Analysts at Jefferies, Baird, and William Blair have downgraded Ultragenyx to Neutral or In Line ratings, citing the setback in the Phase 3 ASPIRE trial and the company's heavy expense burden.

Announcements· Dec 30

Ultragenyx Pharmaceutical Inc. completed the rolling submission of its Biologics License Application (BLA) to the U.S. FDA for DTX401, an AAV gene therapy candidate for Glycogen Storage Disease Type Ia.
If approved, DTX401 will be the first therapy approved to treat the underlying cause of GSDIa, a rare genetic disorder.
Ultragenyx's BLA submission for DTX401 is supported by data from a study, and the company is awaiting FDA approval.

Technical Analysis· Apr 19

Technical alerts for $RARE include a Shooting Star Candlestick and 5 more alerts, but none are specified.
The stock is expected to pull back to $62.50 and potentially bounce back to $66+.
A top reversal is predicted for $RARE, but the timeframe for this event is uncertain.

Generated by AI

Community

Of the messages about RARE, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	19.23%	13.54%	11.17%	34.48%
Newcomers	80.77%	86.46%	88.83%	65.52%

Regulars· Sep 18

Cantor Fitzgerald raised the price target on $RARE to $39 from $33, citing the approval of FAYUVI as a "much-needed win" for Ultragenyx.
Institutional investors are likely to be bought out by a biopharmaceutical company, potentially at a price of 6X or 7X annual forecasted future sales.
The market is undervaluing Ultragenyx, with a current price that is disconnected from the company's business, and a valuation of around $24 per share is suggested.

Newcomers· Sep 29

The newcomer is setting a price target of $20 for RARE, expecting a surge after a potential PRV sale news.
RARE is undervalued, with a market cap of $1.4B despite generating $700M in trailing revenue, and is expected to have a valuation reset due to its pipeline and existing commercial suite.
The newcomer is hopeful that RARE can hold its price, and believes that the company's future looks brighter than its current share price suggests, with a potential price target of $45.

Generated by AI

Ultragenyx Pharmaceutical

Social

Sep 29

Bullish· Sep 22

Bearish· Sep 18

Analysts· Sep 3

Announcements· Dec 30

Technical Analysis· Apr 19

Regulars· Sep 18

Newcomers· Sep 29

H.C. Wainwright reiterates Ultragenyx stock rating on FDA approval

RARE Stock Climbs This Week As Investors Look Past Trial Failure To Gene Therapy Launches, Trial Results

FDA Approves Fayuvi. What Does It Mean for Ultragenyx (RARE)’s 2027 Profitability Target?

Analysts Offer Insights on Healthcare Companies: Helus Pharma (HELP), Ultragenyx Pharmaceutical (RARE) and Novavax (NVAX)

Analysts Offer Insights on Healthcare Companies: Merck & Company (MRK), Envista Holdings (NVST) and Ultragenyx Pharmaceutical (RARE)

Weekly Note: Ultragenyx (RARE): FAYUVI Full Approval Clears The Binary: Upgrade To Buy, Execute Stage Two

Also Discussed

Ultragenyx Pharmaceutical Inc.

Company Information

Location

H.C. Wainwright reiterates Ultragenyx stock rating on FDA approval

RARE Stock Climbs This Week As Investors Look Past Trial Failure To Gene Therapy Launches, Trial Results

FDA Approves Fayuvi. What Does It Mean for Ultragenyx (RARE)’s 2027 Profitability Target?

Analysts Offer Insights on Healthcare Companies: Helus Pharma (HELP), Ultragenyx Pharmaceutical (RARE) and Novavax (NVAX)

Analysts Offer Insights on Healthcare Companies: Merck & Company (MRK), Envista Holdings (NVST) and Ultragenyx Pharmaceutical (RARE)

Weekly Note: Ultragenyx (RARE): FAYUVI Full Approval Clears The Binary: Upgrade To Buy, Execute Stage Two

Also Discussed

Social

Sep 29

Bullish· Sep 22

Bearish· Sep 18

Analysts· Sep 3

Announcements· Dec 30

Technical Analysis· Apr 19

Regulars· Sep 18

Newcomers· Sep 29